XLO earnings analysis
What we found in XLO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Xilio delivered strong second-quarter revenue growth and a materially narrower loss, with collaboration and license revenue of $18.692 million and diluted EPS of negative $0.33. The FDA’s clearance of the XTX501 IND and an expected cash runway into Q1 2028 support near-term development, but the business remains dependent on collaboration milestones, potential warrant proceeds and future capital. Continued losses, single-source China manufacturing exposure, evolving tariff restrictions and regulatory execution risk temper the improving quarterly financial trend.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue accelerated materially
- Second-quarter collaboration and license revenue was $18.692 million, up $10.608 million, or 131.2%, from $8.084 million in Q2 2025 and up $5.692 million, or 43.8%, from $13.000 million in Q1 2026.
- EPS loss narrowed
- Diluted EPS improved to negative $0.33 from negative $2.24 in Q2 2025, a $1.91 improvement, and from negative $0.58 in Q1 2026, a $0.25 improvement.
- Net loss narrowed sharply
- Net loss was $6.373 million in Q2 2026 versus $15.844 million in Q2 2025, a reduction of $9.471 million, or 59.8%.
- Runway extends into Q1 2028
- Cash and cash equivalents totaled $136.0 million at June 30, 2026. Management expects this balance plus the $6.0 million AbbVie milestone received in Q3 2026 to fund operating expenses and capital expenditures into Q1 2028.
- XTX501 advances toward clinical dosing
- The FDA cleared the XTX501 IND, and management expects to initiate XTX501 dosing in the second half of 2026.
- Disclosure controls remain effective
- Controls and procedures were concluded effective at a reasonable assurance level as of June 30, 2026, with no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continuing losses and financing need
- The company reported an accumulated deficit of $434.7 million as of June 30, 2026 and net losses of $15.9 million for the six months ended June 30, 2026. Management expects operating losses and negative operating cash flows to continue for the foreseeable future and has no committed external funding sources.
- Potential dilution and funding dependence
- The cash runway estimate excludes up to $36.2 million of potential gross proceeds from outstanding Series C warrants, which have a current exercise price of $10.50 per warrant. If the warrants are not exercised or additional capital is unavailable, the company could exhaust resources sooner than anticipated.
- China CDMO concentration risk
- WuXi Biologics is the company’s current single manufacturing-process provider and operates in China. The June 8, 2026 update to the Department of Defense/War 1260H list included WuXi AppTec, and the filing warns that a future listing could include WuXi Biologics and disrupt supply or clinical timelines.
- New tariff exposure
- Beginning September 29, 2026, a 100% U.S. tariff is scheduled to apply to certain patented pharmaceuticals, biologics, active pharmaceutical ingredients and key starting materials for companies not covered by specified exemptions or qualifying arrangements. The company warns that tariffs and trade restrictions could increase costs or delay clinical development.
- Regulatory agency disruption
- The federal government shutdown on October 1, 2025 lasted 43 days, during which the FDA stated it could not accept certain fiscal-year 2026 fee-based submissions. Future FDA staffing reductions, funding cuts or shutdowns could delay IND reviews and other regulatory activities.
- No approved products or product revenue
- The company has not generated product-sales revenue and does not expect product revenue for at least the next several years, if at all. All programs remain in clinical or preclinical development, leaving future value dependent on successful clinical and regulatory milestones.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.33
- Gross margin
- 100.0%
- Segment
- Collaboration and license revenue: $18.692 million; no operating-segment revenue breakdown disclosed.
What they said about what is next.
No explicit numeric revenue or EPS guidance was provided. Management expects cash and cash equivalents of $136.0 million as of June 30, 2026, together with a $6.0 million AbbVie development milestone received in Q3 2026, to fund operations and capital expenditures into Q1 2028. Potential additional funding includes up to $36.2 million from Series C warrant exercises and up to $31.0 million in near-term AbbVie milestones and option-extension fees through the first half of 2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 12, 2026
- Xilio Therapeutics reported strong Q4 2026 results with revenues of $13.7 million, a substantial increase from the $2.9 million reported in Q4 2025, driven primarily by collaboration and licensing revenues. Notably, the…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing XLO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever